Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Celcuity ( (CELC) ) has issued an announcement.
On June 30, 2025, Celcuity Inc. announced clinical data from two early phase studies of gedatolisib, a drug under investigation for metastatic castration-resistant prostate cancer. The preliminary Phase 1 results showed a 66% six-month radiographic progression-free survival rate, with no treatment-related adverse events leading to discontinuation. The company plans to expand the study to determine the recommended Phase 2 dose, which could impact its market positioning and stakeholder interests.
The most recent analyst rating on (CELC) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Celcuity stock, see the CELC Stock Forecast page.
Spark’s Take on CELC Stock
According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.
Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.
To see Spark’s full report on CELC stock, click here.
More about Celcuity
Celcuity Inc. operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company is primarily engaged in advancing its lead product candidate, gedatolisib, which is being evaluated in combination with other cancer therapies.
Average Trading Volume: 233,854
Technical Sentiment Signal: Hold
Current Market Cap: $474.8M
See more data about CELC stock on TipRanks’ Stock Analysis page.